CME Group Inc. (NASDAQ:CME) finished Wednesday with an addition of $1.43 to close at $206.52, an upside of 0.70 percent. An average of 1,644,380 shares of common stock have been traded in the last five days. There was a gain of $6.85 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 1,535,615 shares traded, while the 50-day average volume stands at 1,637,838.
CME stock has increased by 13.27% in the last month. The company shares reached their 1-month lowest point of $180.11 on 07/12/23. With the stock rallying to its 52-week high on 08/09/23, shares of the company touched a low of $162.26 and a high of $209.24 in 52 weeks. It has reached a new high 20 times so far this year and achieved 22.81% or $38.36 in price. In spite of this, the price is down -1.30% from the 52-week high.
Insider Transactions
CME stock investors should be aware that CME Group Inc. (CME) stock had its last reported insider trading activity 1 day ago on Aug 09. In this transaction, the insider spent $154,565. Sr MD & Chief HR Officer, Piell Hilda Harris, disposed of 4,477 shares at a price of $207.98 on Aug 07. The insider now owns more than $931,126 worth of shares. Prior to that, Chief Information Officer Cutinho Sunil went on to Sale 9,328 shares at $198.66 each on Jul 28. An amount of $1,853,100 was transacted.
Valuation Metrics
CME Group Inc. (CME) has a trailing price-to-earnings (P/E) ratio of 25.23. The stock’s beta is 0.42. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 7.35, the price-to-book (PB) ratio at 2.66.
Financial Health
The quick ratio of CME Group Inc. for the three months ended June 29 was 1.00, and the current ratio was 1.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.13 and a total debt to equity ratio of 0.13 for the quarter ending June 29. Its gross profit as reported stood at $2.0 billion compared to revenue of $5.02 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, CME Group Inc.’s return on assets was 1.80%.
Earnings Surprise
For the three-month period that ended June 29, CME Group Inc. had $3.42 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $767.8 million in the quarter, while revenues of $872.7 million were grew 14.81%. The analyst consensus anticipated CME Group Inc.’s latest quarter earnings to come in at $2.2 per share, but it turned out to be $2.3, a 4.50% surprise. For the quarter, EBITDA amounted to $927.9 million. Shareholders own equity worth $359.75 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at CME Group Inc. (CME) price momentum. RSI 9-day as of the close on 09 August was 76.12%, suggesting the stock is Overbought, with historical volatility in this time frame at 14.46%.
As of today, CME’s price is $205.58 +3.43% or $6.85 from its 5-day moving average. CME is currently trading +13.90% higher than its 20-day SMA and +10.31% higher than its 100-day SMA. However, the stock’s current price level is +16.90% above the SMA50 and +21.20% above the SMA200.
The stochastic %K and %D were 88.69% and 89.96%, respectively, and the average true range (ATR) was 3.59. With the 14-day stochastic at 87.83% and the average true range at 3.39, the RSI (14) stands at 74.66%. The stock has reached 3.79 on the 9-day MACD Oscillator while the 14-day reading was at 7.04.
Analyst Ratings
Barclays launched coverage on CME Group Inc. (NASDAQ: CME) in its analyst report released on June 28, 2023. The firm assigned the stock an Overweight rating. The consensus rating for CME Group Inc. (CME) among analysts is Overweight. According to current brokerage recommendations, 2 brokerage firms advise that investors sell CME, while 6 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 8 others rate it as a “buy”.
